CheemaH., BargmanJ.M.Cancer antigen 125 as a biomarker in peritoneal dialysis: mesothelial cell health or death?Perit Dial Int2013; 33: 349–52.
2.
KoomenG.C., BetjesM.G., ZemelD., KredietR.T., HoekF.J.Cancer antigen 125 is locally produced in the peritoneal cavity during continuous ambulatory peritoneal dialysis.Perit Dial Int1994; 14: 132–6.
3.
KabawatS.E., BastR.C.Jr., BhanA.K., WelchW.R., KnappR.C., ColvinR.B.Tissue distribution of a coelomic-epitheliumrelated antigen recognized by the monoclonal antibody OC125.Int J Gynecol Pathol1983; 2: 275–85.
4.
ZeillemakerA.M., VerbrughH.A., Hoynck van PapendrechtA.A., LeguitP.CA 125 secretion by peritoneal mesothelial cells.J Clin Pathol1994; 47: 263–5.
5.
BreborowiczA., BreborowiczM., PydaM., PołubinskaA., OreopoulosD.Limitations of CA125 as an index of peritoneal mesothelial cell mass.nephron Clin Pract2005; 100: c46–51.
6.
KredietR.T., ZweersM.M., van WestrhenenR., ZegwaardA., StruijkD.G.Effects of reducing the lactate and glucose content of PD solutions on the peritoneum. Is the future GLAD?NDT Plus2008: 1(Suppl 4): iv56–62.
7.
KawanishiK., HondaK., TsukadaM., OdaH., NittaK.Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.Perit Dial Int2013; 33: 242–51.
